Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2008

View Archived Issues

Responses to nemifitide seen in patients with severe, refractory depression

Volociximab-gemcitabine combination feasible in metastatic pancreatic cancer

Satisfactory therapeutic window of Micromet's BiTE antibody muS-110

Small molecule CCR3 antagonist shows preclinical efficacy for the treatment of asthma

New agents for treating neurological disorders described in recent patent literature

Once-daily mesalamine for active ulcerative colitis now available in Canada

New anticancer agents disclosed in recent patents

Theratechnologies reviews strategic alternatives to enhance shareholder value

Topigen initiates European phase II trial of TPI-ASM-8 in asthma patients

Lipid reports favorable results from preclinical study of delipidated autologous virus vaccine

Phase II trial demonstrates Davanat's benefits in combination with other chemotherapeutics

Ipsen withdraws application to EMEA for extension of indication for Nutropin AQ

Oasmia receives final advice from EMEA regarding phase III program for Paclical

FDA grants priority review for Millennium's Velcade for multiple myeloma

DOR BioPharma achieves 2-year stability milestone for its ricin toxin vaccine

FDA issues nonapprovable letter to Impax for Vadova for Parkinson's disease

Tigris Pharmaceuticals initiates phase I study of AFP-464 for treatment of solid tumors

Phosphagenics announces results from preclinical study of APA-01 and atorvastatin

First patients treated in Cytori's stem and regenerative cell heart attack study

Banyu obtains additional indication approval for Singulair in allergic rhinitis

Somaxon submits NDA for Silenor, a drug candidate for insomnia therapy

Novel agents for arthritic disorders disclosed in recent patents

GlaxoSmithKline obtains approval for Amerge in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...